Business
Exercise of warrants
Exercise of warrants.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 6997W Oxford Biomedica PLC 18 April 2019 \n\n \n \nExercise of warrants\nLondon, UK - 18 April 2019: Oxford Biomedica plc (\"Oxford Biomedica\", \"the Company\" or \"the Group\") (LSE:OXB), a leading gene and cell therapy group, announces that it has received notification from Oaktree Capital Management (\"Oaktree\") to exercise warrants representing 2,689,686 ordinary shares of 50p each (\"Ordinary Shares\") in the Company for total consideration of £1,344,843. The exercise price of the warrants was 50p per warrant.\nApplications have been made for the Ordinary Shares to be admitted to the premium listing segment of the Official List of the Financial Conduct Authority and to be admitted to trading on the main market for listed securities of the London Stock Exchange plc (together, \"Admission\"). Admission is expected to take place at 8.00 a.m. on 26 April 2019.\n \nTotal voting rights\nFollowing Admission, the Company's issued share capital will consist of 68,860,324 ordinary shares of 50p each. The new Ordinary Shares will rank pari passu with the existing ordinary shares. There are no ordinary shares held in treasury. Accordingly, the total number of voting rights in Oxford Biomedica plc at Admission will be 68,860,324.\n \nThe above figure 68,860,324 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Biomedica plc under the FCA's Disclosure Guidance and Transparency Rules.\n \n-Ends-\n \n\n\n\nFor further information, please contact:\n\n\n \n\n\n\n\n \nOxford Biomedica plc:\nStuart Paynter, Company Secretary\n\n\n \nTel: +44 (0)1865 783 000\n\n\n\n \n \nAbout Oxford Biomedica\n \nOxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the \"Group\") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The ...